Similarly, the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) [14] secondary analysis by Halperin et al. reported that rivaroxaban was non-inferior to warfarin for stroke/systemic embolism prevention in patients aged ≥75 years (HR: 0.80; 95% CI: 0.63-1.02), while bleeding risks were comparable (HR: 1.11; 95% CI: 0.92-1.34). The gene discussed is F10; the disease is stroke disorder.